CHCWM – Cancer & Hematology Centers of West Michigan

KN-4802 (Kinnate Biopharma Inc.)

 Description:   Phase I/Ib, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

Mechanism of Action: Small molecule pan-FGFR inhibitor

Target Patient Population:  Any tumor type with FGFR2 or FGFR3 gene abnormalities

Study Design:  Study drug is given orally